You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Iveric Bio receives new therapy designation for avacincaptad pegol

Iveric Bio (Iveric) has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status for avacincaptad pegol (ACP).